Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer

Chiara Falcomata1,2,16, Stefanie Bärthel1,2,16, Angelika Ulrich1,2+, Sandra Diersch3, Christian Veltkamp1,2,16, Lena Rad1,2,16, Fabio Boniol1,2,16, Myriam Solar4, Katja Steiger5,7, Barbara Seidler1,3,16, Magdalena Zukowska1,3,16, Joanna Madej1,2,16, Mingsong Wang1,3,16, Rupert Öllinger6,7,16, Roman Maresch6,7,16, Maxim Barenboim6,8, Stefan Eser1-3, Markus Tschurtschenthaler1,2,16, Arianeb Mehrabi9, Stephanie Roessler10, Benjamin Goeppert10, Alexander Kind11, Angelika Schnieke11, Maria S. Robles12, Allan Bradley13, Roland M. Schmid3, Marc Schmidt-Supprian7,14,16, Maximilian Reichert3,7,16, Wilko Weichert5,7, Owen J. Sansom4,15, Jennifer P. Morton4,15, Roland Rad6,7,16, Günter Schneider3,7,17,*, Dieter Saur1-3,16,*

1Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; 2Chair of Translational Cancer Research and Institute for Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technische Universität München, Ismaninger Str. 22, 81675 Munich, Germany; 3Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 Munich, Germany; 4Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK; 5Institute of Pathology, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675 München, Germany; 6Institute of Molecular Oncology and Functional Genomics, School of Medicine, Technische Universität München, 81675 Munich, Germany; 7German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; 8Department of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technische Universität München, School of Medicine, 80804 Munich, Germany; 9Department of Surgery and 10Institute of Pathology, Universität Heidelberg, Im Neuenheimer Feld 110 and 224, 69120 Heidelberg, Germany; 11Livestock Biotechnology, Technische Universität München, Liesel-Beckmann Str. 1, 85354 Freising, Germany, 12Institute of Medical Psychology, Faculty of Medicine, LMU Munich, Goethe Str. 31, 80336 Munich, Germany; 13Wellcome Trust Sanger Institute, Genome Campus, Hinxton-Cambridge CB10 1SA, U.K, 14Institute of Experimental Hematology, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany; 15Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK; 16Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany; 17University Medical Center Göttingen, Department of General, Visceral and Pediatric Surgery, 37075 Göttingen, Germany; 18Center for Protein Assemblies (CPA), Technische Universität München, Ernst-Otto-Fischer Str. 8, 85747 Garching, Germany.

†These authors contributed equally to this work and are co-first authors.
‡These authors contributed equally to this work and are co-senior authors.

Running Title: p27 blocks bile duct cancer formation
**Keywords:** transposon mutagenesis, forward genetic screen, genetically engineered mouse models, tissue-specific carcinogenesis, biliary tract cancer, extrahepatic cholangiocarcinoma, tumor suppressor barriers.

*Correspondence to:*

Dieter Saur or Günter Schneider, Chair of Translational Cancer Research and Institute for Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technische Universität München, Ismaninger Str. 22, 81675 Munich, Germany. Tel: +49 89 4140 5255, Fax: +49 89 4140 7289, E-mail: dieter.saur@tum.de and guenter.schneider@tum.de

**Authors’ Disclosures**

The authors declare that they have no competing financial interests. Correspondence and requests for materials should be addressed to D.S. (dieter.saur@tum.de) or G.S. (guenter.schneider@tum.de)

**Acknowledgments**

We would like to thank Dr. J. Roberts, Dr. T. Jacks, Dr. J. Jonkers, Dr. A. Berns, Dr. A. Lowy, Dr. T. Mak, Dr. L. Luo, Dr. H. Zeng and Dr. D. Tuveson for providing transgenic animals, and J. Götzfried, M. Mielke, A. Hering and O. Seelbach for excellent technical assistance. This work was supported by funding from Deutsche Forschungsgemeinschaft (DFG SA 1374/4-3 to D.S., SFB 1321 Project-ID 329628492, P06, P11, P13 to M.R., M.S.S., G.S. and D.S., and S1 to W.W. and K.S.), the German Cancer Consortium (DKTK to K.S., M.S.S., W.W., R.R. G.S. and D.S.), the European Research Council (ERC CoG No. 648521 to D.S.), Cancer Research UK core funding to the CRUK Beatson Institute (A17196) and Cancer Research UK core funding to O.S. (A21139).
Abstract

Biliary tract cancer ranks among the most lethal human malignancies, representing an unmet clinical need. Its abysmal prognosis is tied to an increasing incidence and a fundamental lack of mechanistic knowledge regarding the molecular basis of the disease. Here, we show that the Pdx1-positive extrahepatic biliary epithelium is highly susceptible towards transformation by activated Pik3ca^{H1047R}, but refractory to oncogenic Kras^{G12D}. Using genome-wide transposon screens and genetic loss-of-function experiments, we discover context-dependent genetic interactions that drive extrahepatic cholangiocarcinoma (ECC) and show that PI3K-signaling output strength and repression of the tumor-suppressor p27^{Kip1} are critical context-specific determinants of tumor formation. This contrasts the pancreas, where oncogenic Kras in concert with Trp53-loss are key cancer-drivers. Notably, inactivation of p27^{Kip1} permits Kras^{G12D}-driven ECC development. These studies provide a mechanistic link between PI3K-signaling, tissue-specific tumor suppressor barriers, and ECC pathogenesis, and present a novel genetic model of autochthonous ECC and genes driving this highly lethal tumor-subtype.

Significance

The first genetically engineered conditional mouse model for extrahepatic bile duct cancer. Transposon mutagenesis-based identification of ECC cancer genes. PI3K signaling output is a critical determinant for ECC development. p27^{Kip1} is a central roadblock for context-specific bile duct cancer formation.
Introduction

Adenocarcinomas of the bile duct express markers of cholangiocyte differentiation and are therefore termed cholangiocarcinomas (CC). They are classified into three subtypes, depending on their distinct anatomical location within the biliary tree: intrahepatic cholangiocarcinoma (ICC; comprising 10-20% of all cases), and extrahepatic CC (ECC) with perihilar (PCC, 50-60%) and distal (DCC, 20-30%) location (1). This group of cancers is heterogeneous, and the anatomical subtypes differ not only in their anatomical site, but also in their epidemiology, pathogenesis, genetic and clinical characteristics. This reflects in different treatment options and therapeutic responses (1-3). CC develops from cholangiocytes or their progenitor cells lining the biliary tract, which arise from two distinct developmental origins. The intrahepatic biliary tree derives from liver progenitor cells, called hepatoblasts, which give rise to hepatocytes and intrahepatic cholangiocytes (4). The extrahepatic part of the biliary tree develops before the intrahepatic tract and both systems merge at the level of the hepatic duct during embryonic development. Cholangiocytes lining the extrahepatic bile ducts share a common origin with the ventral pancreas, but not the liver. They derive from Pdx1 positive progenitor cells from the caudal part of the ventral foregut endoderm (4,5).

The incidence of biliary tract cancer (BTC), which is highest in South/East Asia and South America, increases worldwide (1,6). In the western world, BTC accounts for 3% of all gastrointestinal tumors with ECC being the most common type of BTC (1,2). Despite modern multimodal treatment regimes, mortality rates of bile duct cancer have remained stubbornly unchanged for the last three decades, with approximately 10% of patients surviving 5 years (1-3,7). This contrasts other solid tumor entities such as colorectal cancers, where death rates have decreased more than 40% over the past 20 years (8). Surgical resection is the procedure of choice. However, early symptoms are unspecific and, by the time of diagnosis, most tumors are not surgically resectable. Consequently, there is an urgent need to identify and validate actionable cancer drivers as novel therapeutic targets.

Comprehensive molecular tumor profiling has greatly improved our understanding of the processes underlying tumorigenesis in the biliary tract (1,3,9-12). These studies revealed a subtype-associated prevalence of genomic alterations, methylation pattern and gene expression profiles, in line with the observed clinicopathological differences.
between ICC and ECC (2,3,11,13). However, we are still far from understanding the nature of the described genetic alterations, their functional relevance, their downstream effectors and their role in oncogenic networks. Specifically, mechanistic knowledge concerning true cancer drivers remains extremely poor for ECC, which is in part due to a lack of genetically defined animal models that accurately mimic this tumor subtype. Improving the survival of patients with ECC will therefore depend on unbiased functional systematic approaches in relevant model systems to identify the genes and pathways that drive the disease.

To this end, we generated a Cre/loxP-based genetically engineered mouse model (GEMM) of bile duct cancer with consequent extrahepatic localization and performed a forward genetic screen using the conditional piggyBac transposon mutagenesis system (14,15). Analysis of recurrent transposon insertion sites identified numerous cancer genes and pathways, including known and new ECC-related genes, providing a unique resource for novel potential therapeutic targets. We used loss-of-function experiments in GEMMs to validate selected therapeutically tractable pathways and uncovered unexpected context-specific oncogenic networks, genetic dependencies and tumor suppressive functions in ECC development.
Results

Pdx1-Cre mediated genetic manipulation of the extrahepatic biliary epithelium

To target the extrahepatic biliary epithelium, we used transgenic mice expressing Cre recombinase under the control of the murine Pdx1 promoter (Pdx1-Cre; Figure 1A, B and Supplementary Figure S1A). We evaluated the patterns of Pdx1-Cre transgene expression using two different Cre activatable reporter alleles. A lox-stop-lox (LSL) silenced fluorescent tdTomato reporter line (LSL-R26tdTomato/+; Figure 1A) (17) and a switchable floxed double color fluorescent tdTomato-EGFP Cre reporter allele (R26mT-mG) that replaces the expression of tdTomato with EGFP after Cre-mediated recombination (Figure 1B) (18). Macroscopic fluorescence stereomicroscopy of Pdx1-Cre;LSL-R26tdTomato/+ mice revealed Cre-mediated recombination of the extrahepatic biliary tree, the pancreas and duodenum in vivo, as evidenced by tdTomato expression (Figure 1A). Using genetic Pdx1-Cre;R26mT-mG reporter animals we confirmed Cre-mediated recombination specifically in the extrahepatic bile duct histologically, as shown by expression of membrane-tagged EGFP in CK19 positive biliary epithelial cells and peribiliary glands (Figure 1B). In contrast, stromal cells remained unrecombined and expressed membrane-tagged tdTomato (Figure 1B). No recombination was observed by fluorescence microscopy and genotyping PCR in liver, lung, kidney, heart, colon, brain and spleen (Fig. 1 and Supplementary Fig. S1A).

Activation of oncogenic Pik3caH1047R but not KrasG12D induces premalignant biliary intraepithelial neoplasia (BilIN)

Molecular profiling of human BTC revealed a large set of putative cancer drivers that are enriched for RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, TGFβ and growth factor receptor signaling pathways, as well as epigenetic regulators and DNA damage response genes (1,3,10,12,13,19-23). However, the functional consequences of these putative driver alterations and their relevance for ECC development have not been investigated yet in vivo. To test whether constitutive activation of oncogenic Kras or Pik3ca, which regulate two of the most frequently altered oncogenic pathways in BTC (3), is capable to transform the extrahepatic biliary epithelium in vivo, we employed the Pdx1-Cre model. We used a LSL silenced oncogenic Pik3caH1047R allele as a knock-in at the Rosa26 locus (LSL-Pik3caH1047R/+ line; Figure 1C, Supplementary graphical abstract and Supplementary Figure S1A; (24)) to explore the mechanistic role of the
PI3K-AKT-mTOR signaling pathway in ECC development. This mouse line carries a histidine (H) to arginine (R) mutation at codon 1047 (H1047R) within the highly conserved kinase domain of Pik3ca, resulting in increased catalytic activity and enhanced PI3K downstream signaling (24,25). To achieve conditional activation of oncogenic Kras in the Pdx1-Cre lineage, we employed a latent KrasG12D allele as a knock-in at the endogenous Kras locus (LSL-KrasG12D/+ line; Figure 1D, Supplementary Figure S1A and graphical abstract; (16)). This mouse line carries a glycine (G) to aspartic acid (D) mutation at codon 12 (G12D) of Kras, which is refractory to GTPase-activating protein (GAP)-induced GTP hydrolysis, favoring an active state (26). Expression of mutationally-activated Pik3caH1047R in Pdx1-Cre;LSL-Pik3caH1047R/+ mice revealed no overt phenotype after birth. However, adult animals developed an enlarged extrahepatic bile duct and biliary intraepithelial neoplasia (BilIN) (Fig. 1C and Supplementary Fig. S1B), a precursor lesion of ECC (27) with complete penetrance. The grade of BilIN lesions increased over time; from low-grade BilINs in young animals to high-grade lesions in nine months old animals. In contrast to the Pik3caH1047R model, the extrahepatic bile duct was refractory towards neoplastic transformation by oncogenic KrasG12D (Fig. 1D and Supplementary Fig. S1B). Instead, KrasG12D expression in the Pdx1-Cre lineage induced only acinar-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN), a precursor to invasive pancreatic ductal adenocarcinoma (PDAC). We observed similar lesions in a previous study in the pancreas after selective activation of Pik3caH1047R in pancreatic precursor cells using a Ptf1aCre line (24).

To compare Pik3ca expression levels between mutant and wildtype tissue and assess the activation status of the PI3K signaling pathway in Pik3caH1047R- and KrasG12D- mutant mice, we analyzed the common bile duct by immunohistochemistry (Fig. 1C-E and Supplementary Fig. S1C). As expected, Pik3ca expression levels were moderately increased in the bile duct of Pik3caH1047R-mutant animals in comparison to wildtype mice (Supplementary Fig. S1C). In line we observed activation of key downstream effectors of PI3K signaling, such as pAKT-T308, pAKT-S473 and pGSK3β-S9 (Figure 1C). Interestingly, PI3K signaling is also activated in the extrahepatic bile duct of KrasG12D mutant and wildtype mice, albeit to a lesser extent in the wildtypes (Figure 1D and E). This indicates that signaling thresholds and tumor suppressor barriers might be important determinants of oncogenic transformation.
\textit{Pdx1-Cre} mediated activation of oncogenic Pik3ca^{H1047R} or Kras^{G12D} in the pancreas resulted in very similar patterns of ADM and PanIN induction (Supplementary Fig. S2A, B). Surrogate markers of PI3K signaling were almost identical in Pik3ca^{H1047R} and Kras^{G12D}-driven tumors, as shown by phospho-specific pAKT-T308, pAKT-S473 and pGSK3β-S9 stainings, indicating an important role of this pathway for PDAC formation (Supplementary Fig. S2B, C). In line, previous studies validated its essential role for PanIN and PDAC development by genetic loss of function experiments in Kras^{G12D}-driven genetically engineered mouse models (24,28).

To assess the signaling output of the canonical MAPK pathway, we analyzed ERK 1/2 activation using a phosphorylation-specific antibody. MAPK pathway signaling was decreased in the bile duct of the \textit{Pik3ca^{H1047R}} model compared to wildtype animals. In the pancreas, we observed strong ERK 1/2 activation in Kras^{G12D}-driven PanINs and PDAC, whereas Pik3ca^{H1047R}-induced tumors showed lower phosphorylation levels (Supplementary Fig. S2B-D).

Taken together, our data demonstrate that activation of oncogenic Pik3ca^{H1047R} in the extrahepatic bile duct models the full spectrum of human BilIN precursor lesion progression. In addition, they uncover fundamental different context-specific oncogenic vulnerabilities of the extrahepatic bile duct and the pancreas, although both organs originate from the same Pdx-1 positive precursor cell lineage.

Expression of mutant Pik3ca^{H1047R} induces invasive extrahepatic cholangiocarcinoma (ECC)

To test whether \textit{Pik3ca^{H1047R}} is capable of inducing ECC, we aged \textit{Pdx1-Cre;LSL-Pik3ca^{H1047R/+}} mice. Within 800 days, 90% of the \textit{Pik3ca^{H1047R}} mutant animals in the tumor watch cohort developed extrahepatic bile duct cancer (Figure 2A-D and supplementary graphical abstract) displaying strong PI3K/AKT pathway activation, as demonstrated by key down-stream surrogates of PI3K signaling: AKT-T308/S473 and GSK3β-S9 phosphorylation (Figure 2B). ECCs recapitulated the full spectrum of the human disease, ranging from well-differentiated stroma-rich ductal adenocarcinomas to more undifferentiated tumors (Figure 2B and Supplementary Figure S2) (27,29). Notably, at the time of necropsy all animals developing ECC displayed cholestasis with bile duct obstruction and jaundice. This caused termination of the experiment as humane endpoint. Thus the new \textit{Pdx1-Cre;LSL-Pik3ca^{H1047R/+}} model faithfully mimics
human ECC; from precursor lesion formation and progression to full blown bile duct obstructing invasive cancers, with a characteristic strong desmoplastic stromal reaction (27,29).

Comparison of tumor formation of Pik3ca$^{H1047R}$ and Kras$^{G12D}$ mutant animals revealed striking differences. Although survival times were nearly identical, Kras$^{G12D}$ mutant mice developed exclusively invasive tumors of the pancreas, recapitulating pancreatic ductal adenocarcinoma (PDAC), but not biliary tract cancer (Fig. 2C-D, Supplementary Fig. S3A and graphical abstract). We never observed high-grade BillN lesions or invasive ECC in Kras$^{G12D}$ mutant animals aged up to 800 days. This unexpected resistance of the extrahepatic biliary epithelium against oncogenic transformation by Kras$^{G12D}$ contrasts other tissue types, such as the lung or the intrahepatic biliary tract, which are highly susceptible for Kras$^{G12D}$-induced tumorigenesis (24,30,31).

To assess tumor development in other Pdx1-Cre recombined organs in Pik3ca$^{H1047R}$ mutant mice (see Fig. 1A and Supplementary Fig. S1A), we performed a comprehensive macroscopic and microscopic histopathological analysis and observed PDAC development in 60%, hyperplasia of the duodenal mucosa in 100%, and duodenal adenoma formation in 10% of the investigated double transgenic animals (Fig. 2D and Supplementary Fig. S3A-C). Histopathologic analyses revealed that Pik3ca$^{H1047R}$-induced tumors were indistinguishable from Kras$^{G12D}$-driven PDAC and showed the full spectrum of the disease including ADM and PanIN lesions (Fig. 2 and Supplementary Fig. S3A).

Together, these data support the notion that PI3K signaling is an important functional driver of ECC development and suggest that distinct context-specific tumor suppressor barriers and/or signaling thresholds are operative in the pancreas and the extrahepatic bile duct. This is remarkable due to the shared developmental origin of the pancreas and the extrahepatic bile duct and therefore, a common cell of origin of both tissue types.

**Oncogenic PI3K signaling activates a senescence program in the extrahepatic bile duct that is independent of the p53 pathway**

We next analyzed tissue-specific tumor suppressive mechanisms in the Pik3ca$^{H1047R}$ model. Expression of oncogenic Pik3ca$^{H1047R}$ induced a senescence program in the
extrahepatic biliary epithelium, similar to the activation of oncogenic Kras\textsuperscript{G12D} in the pancreas (Figure 3A and supplementary graphical abstract) (32). Low-grade BilIN lesions, but not wildtype epithelium, stained positive for senescence-associated β-galactosidase (SA-β-Gal), which has been shown to be a reliable oncogene-induced senescence biomarker (Figure 3A) (33). Oncogene-induced senescence (OIS) can be induced by the tumor suppressor Trp53 and its target gene p21\textsuperscript{Cip1}. Interestingly, and in contrast to Pik3ca\textsuperscript{H1047R} and Kras\textsuperscript{G12D}-induced ADM and PanINs in the pancreas, BilIN lesions lack activation of the canonical Trp53-p21\textsuperscript{Cip1} senescence pathway (Figure 3A) and display significantly reduced levels of apoptotic cell death (Figure 3B, C). Previously, it has been shown that OIS as well as apoptotic cell death is triggered by the p53 network in the pancreas (32,34). The absence of p53 induction and the significantly lower levels of apoptosis in the extrahepatic bile duct versus the pancreas upon Pik3ca\textsuperscript{H1047R} activation indicates fundamental context-dependent differences in the genetic networks and tumor suppressor barriers that prevent tumor formation in both organs (supplementary graphical abstract).

To elucidate the role of the p53 pathway in ECC and PDAC formation functionally, we inactivated Trp53 genetically using floxed Trp53 mice (35). Strikingly, at the humane endpoint, we observed a significant reduced survival of Trp53 deleted animals and a shift of the tumor spectrum from ECC to PDAC in the Pik3ca\textsuperscript{H1047R} model, whereas Kras\textsuperscript{G12D};Trp53\textsuperscript{f/+} animals again developed PDAC only (Figure 3D-G and supplementary graphical abstract). To investigate the timing and order of BilIN/PanIN and ECC/PDAC formation in this model, we analyzed Pik3ca\textsuperscript{H1047R};Trp53\textsuperscript{f/+} mice without clinical signs of cancer development at two selected early timepoints. This revealed widespread occurrence of low and high grade BilIN lesions along the extrahepatic bile duct already in 1,5 months old animals, whereas only few ADMs and even less low grade PanIN lesions were present in the pancreas (Supplementary Fig. S4A). Nevertheless, most Trp53 deleted animals at the endpoint displayed PDAC and BilINs, but not invasive ECC (Fig. 3E). Only one mouse at an age of 3 months developed invasive PDAC and ECC in parallel in the same animal (Supplementary Fig. S4B). This indicates that BilIN development may precede PanINs; however, deletion of Trp53 accelerates progression of low-grade PanIN precursor lesions to invasive pancreatic cancer substantially leading to a shift in the tumor spectrum towards PDAC. These findings support the view of tissue-specific tumor suppressive functions of p53, being a pivotal tumor barrier in the pancreas (supplementary graphical abstract).
Identification of cancer genes in the extrahepatic biliary tract by a piggyBac transposon mutagenesis screen

To study cooperating genetic events in extrahepatic bile duct cancer, we used a previously developed conditional piggyBac transposon-based somatic insertional mutagenesis system in mice with activated Pik3caH1047R (14). To this end, we crossed a LSL silenced piggyBac transposase allele (LSL-R26R) with ATP1-S2 mice, which possess mutagenic ATP1 transposons (14,15). Compound mutant mice were then crossed to the Pdx1-Cre;LSL-Pik3caH1047R/ line (Fig. 4A). To study ECC formation, we aged quadruple mutant mice and observed at the humane endpoint that piggyBac mutagenesis led to an acceleration of Pik3ca-induced cancer development, reduced survival, and a shift in the tumor spectrum towards PDAC (Fig. 4B-D).

To identify transposon insertions, we performed quantitative insertion site sequencing (QISeq) of ECCs as described previously (14). We identified 38,391 non-redundant integrations with a minimal read coverage of 2 (which was set as the threshold for insertion calling). To identify genomic regions that have been hit by transposons more frequently than expected by chance, we carried out TAPDANCE (Transposon Annotation Poisson Distribution Association Network Connectivity Environment) statistical analysis (36), which identified 90 common insertion sites (CISs) (Supplementary Table 1). Figure 4E shows the genome-wide distribution of these insertions and indicates CIS genes within some of the transposon insertion density peaks. Among the 90 TAPDANCE CISs we identified four main gene clusters: (i) insertions into important regulators of PI3K signaling, such as Pten, Lats1 and Frk; (ii) CIS in genes that have been reported to be direct or indirect regulators of p27Kip1 (Cdkn1b) protein abundance, such as Fbxw7 and Ppm1b; (iii) regulators of cell cycle and DNA replication, such as Sfi1, Hdac2 and Hjurp; and (iv) genes of the ubiquitin proteasome system, such as Usp8x, Fbxo30 and Ubr5 (Fig. 4F). Most of the identified genes have not been implicated in epithelial cancer development, but are interesting candidates for further analysis. Vmp1, for example is a downstream target of the PI3K-Akt pathway and implicated in autophagy (37).

To identify significantly enriched interaction networks in ECC, we used the STRING database (http://string-db.org) (38). Thereby, we confirmed enrichment of CIS gene interactions with Pik3ca/Pten and p27Kip1 (Cdkn1b) in ECC (p-value: 5.43e-06; Fig.
4G). Cross-species comparison of the top 24 CIS of the transposon screen with recurrent genetic aberrations found in human bile duct cancer revealed an overlap of 15 altered genes, i.e. *RNF43, FBXW7, PTEN, FAT1, HDAC2, USP9X* and *UBR5* (Supplementary Fig. S5).

The main insertional mutagenesis hits and their function as direct or indirect regulators of PI3K signaling, p27^Kip1 abundance and cell cycle progression are summarized in Supplementary Fig. S6.

**Functional in vivo validation of a context-specific oncogenic Pten-Pik3ca signaling node in ECC**

More than 50% of the ECC tumors (9/17) had insertions in *Pten*. The position and orientation of the ATP1-S2 transposon, which carries a CAG promoter, a splice donor, bidirectional SV40 polyadenylation signals, and two splice acceptors, can be used to predict whether it is likely to drive or disrupt gene transcription (14,15). Disruption of transcription may occur if the transposon inserts into a gene with no CAG promoter relative to the direction of transcription; in this situation, the gene is a putative tumor suppressor gene (TSG). Transcriptional activation may occur if the transposon is sense-oriented and upstream of the translation start site, supporting gene expression from the unidirectional CAG promoter. Analysis of transposon insertion position and orientation in the *Pten* locus revealed a random distribution and sense or antisense orientation, suggesting that gene function is disrupted (Fig. 5A).

To functionally validate *Pten* as a TSG in ECC, we used a genetic loss-of-function approach and inactivated *Pten* in the *Pdx1* lineage using floxed *Pten* mice (*Pten^[f]/^[f]*) (39). *Pdx1-Cre* mediated deletion of *Pten* induced extrahepatic bile duct cancer formation in all animals of the tumor watch cohort analyzed so far (Fig. 5B-D). These findings confirm PI3K-signalling as a driver of ECC development in an independent genetic model and validate our transposon screen functionally.

The inactivation of PTEN argues for the need to select for aberrant enrichment of PI3K signaling during tumor evolution. This note is underscored by the observation that several CISs in the *Pik3ca^[H1047R]* model, such as *Lats1* and *Frk/Rak*, have been shown to regulate the PI3K pathway (40,41) (Fig. 4F,G). To test genetically whether a threshold effect of PI3K-signaling output is indeed a critical determinant of ECC
formation in vivo, we increased the Pik3ca$^{H1047R}$ gene dose and used homozygous Pik3ca$^{H1047R}$ mutant mice, which express the oncogene from both alleles (LSL-Pik3ca$^{H1047R/H1047R}$). This increased Pik3ca expression levels, PI3K signaling output and animal mortality, shortened survival, and further shifted the tumor spectrum from PDAC towards ECC (Fig. 5C-F).

Taken together, these results provide mechanistic in vivo evidence that the canonical PI3K-dependent signaling pathway drives ECC formation in a gene dose dependent manner, arguing that a certain level of PI3K-signaling output strength is important for cancer formation in the extrahepatic bile duct.

**p27$^{Kip1}$ is a tissue-specific barrier of tumor evolution**

Combining data from STRING analysis (http://string-db.org) of the PiggyBac insertional mutagenesis screen and correlative data from literature reviews suggests that p27$^{Kip1}$ (Cdkn1b) is an important barrier in ECC tumorigenesis and a target of several of the identified CISs genes (Fig. 4G and Supplementary Fig. S6). Overactivation of the PI3K-signalling pathway through dysregulated Pik3ca and/or Pten loss, as well as alterations in Fbxw7, Ppm1b and Frk have been shown to regulate p27$^{Kip1}$ protein expression directly or indirectly (41-50). Fbxw7, the substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-ligase complex, for example, is inactivated as a putative TSG by missense mutations in 5-15% of bile duct cancer patients (3,51) and deletion of Fbxw7 results in decreased p27$^{Kip1}$ protein abundance (43). Ppmb1b, a magnesium-dependent protein phosphatase is another positive regulator of p27$^{Kip1}$ abundance (50), eventually via dephosphorylation of p27$^{Kip1}$ at threonine 187 to remove a signal for proteasomal degradation, as described for Ppmb1h, another member of the Ppmb1 family (52).

As demonstrated for Pten (Fig. 5A), the transposon insertion pattern in Fbxw7, Ppm1b and Frk/Rak (Fig. 6A) revealed random distribution across each gene and no orientation bias, predicting that inactivation of these TSGs and positive regulators of p27$^{Kip1}$ are the mechanisms of cancer promotion. Because p27$^{Kip1}$ levels are significantly decreased or absent specifically in ECC patients (53), these observations suggest that p27$^{Kip1}$ might be an important roadblock for extrahepatic biliary cancer formation in mice and men. To test this hypothesis, we analyzed p27$^{Kip1}$ expression levels in the extrahepatic bile duct epithelium by immunohistochemistry in wildtype,
Pik3ca\textsuperscript{H1047R} and Kras\textsuperscript{G12D} mutant animals. In contrast to oncogenic Kras\textsuperscript{G12D}, p27\textsuperscript{Kip1} expression was selectively and significantly downregulated by Pik3ca\textsuperscript{H1047R} (Fig. 6B, C), consistent with previous reports showing that activated PI3K-signalling impairs p27\textsuperscript{Kip1} expression in different tissue types \textit{in vitro} and \textit{in vivo} (42,54,55). To validate these findings, we analyzed the effect of PI3K inhibition on p27\textsuperscript{Kip1} expression levels using primary low-passaged ECC cells derived from the Pik3ca\textsuperscript{H1047R} model. Treatment with the potent and selective pan class I PI3K inhibitor GDC-0941 blocked protein abundance of Skp2 and surrogates of PI3K-signalling, such as Akt-T308, Akt-S473 and p70-S6 Kinase1-S235/236 phosphorylation, and induced p27\textsuperscript{Kip1} expression at the mRNA and protein level (Fig. 6D, E). To investigate whether Skp2 regulates p27\textsuperscript{Kip1} protein abundance in our system, we treated primary low-passaged ECC cells with a specific Skp2 inhibitor (SKP2in C1), which blocks Skp2 substrate binding. This increased p27\textsuperscript{Kip1} protein expression levels in a dose dependent manner, providing additional insights into the mechanism of PI3K mediated p27\textsuperscript{Kip1} downregulation (Fig. 6F).

These data demonstrate that oncogenic PI3K signaling is an important regulator of p27\textsuperscript{Kip1} mRNA and protein abundance in the extrahepatic bile duct and ECC cells. To functionally analyze the role of reduced p27\textsuperscript{Kip1} expression for ECC formation in the extrahepatic bile duct \textit{in vivo}, we used p27\textsuperscript{Kip1} knock-out mice (56). Genetic deletion of one p27\textsuperscript{Kip1} allele in the Pik3ca\textsuperscript{H1047R}-driven model dramatically accelerated tumor formation, shortened mouse survival to a median of 172,5 days and further shifted the tumor spectrum from PDAC towards ECC (Figure 7A, B). All animals in the tumor watch cohort developed invasive ECCs with a desmoplastic stromal reaction (Fig. 7C).

Expression of oncogenic Kras\textsuperscript{G12D} showed no effect on p27\textsuperscript{Kip1} protein abundance in the extrahepatic bile duct and failed to induce ECC formation (Fig. 1, 2, 6B and Supplementary Fig. 1B). To test the hypothesis of a causal relation of p27\textsuperscript{Kip1} as a tissue-specific roadblock for Kras\textsuperscript{G12D} induced tumor formation in biliary epithelium, we deleted p27\textsuperscript{Kip1} in the Pdx1-Cre;Kras\textsuperscript{G12D}-driven model genetically. Inactivation of one p27\textsuperscript{Kip1} allele induced high-grade dysplastic lesions in the extrahepatic bile duct as well as ECC formation in some animals, a phenotype never observed in Kras\textsuperscript{G12D} mice with intact p27\textsuperscript{Kip1}. This reduced median survival of Kras\textsuperscript{G12D+}:p27\textsuperscript{Kip1+/-} mice significantly to 227 days compared to Kras\textsuperscript{G12D+} animals with a median survival of 383 days. Homozygous p27\textsuperscript{Kip1} deletion led to ECC formation in all animals analyzed and further reduced median survival to 112 days (Fig. 7A-C).
Overall, these data validate at the genetic level the notion that p27\textsuperscript{Kip1} is a tissue and context-specific tumor suppressor in the extrahepatic bile duct, and contrasts the pancreas, where p53 represents a critical tumor suppressive barrier; furthermore, they support the view that downregulation of p27\textsuperscript{Kip1} is important for ECC initiation and essential for Kras-induced transformation of the extrahepatic bile duct (supplementary graphical abstract).

To investigate the transcriptional programs involved in the context dependent regulation of the p27\textsuperscript{Kip1} network, we performed RNA-seq analysis of Pik3ca\textsuperscript{H1047R}- and Kras\textsuperscript{G12D}-driven low passaged primary ECC and PDAC cell cultures treated for 48 hours with the PI3K inhibitor GDC-0941 or DMSO as control. We identified profound differences between Pik3ca\textsuperscript{H1047R}- and Kras\textsuperscript{G12D}-driven tumors. Whereas blockade of PI3K signaling induced significant changes of the transcriptional program of Pik3ca\textsuperscript{H1047R}-driven ECCs and PDACs (146 and 142 differentially expressed genes in ECC and PDAC, respectively), it had only minor effects on the transcriptional output of Kras\textsuperscript{G12D}-induced PDAC (22 differentially expressed genes) (Supplementary Fig. S7A, B).

Pathway analysis of the significantly regulated genes revealed substantial changes in RNA binding, processing, splicing and metabolism, as well as E2F targets in Pik3ca\textsuperscript{H1047R}-driven ECCs (top ten pathways ranked by FDR\textsuperscript{q} value shown in Supplementary Fig. S7C). In contrast, Pik3ca\textsuperscript{H1047R}-driven PDAC showed mainly changes of metabolic pathways and the mitochondrion upon PI3K-pathway perturbation. E2F transcription factors have previously been shown to regulate p27\textsuperscript{Kip1} abundance via the transcriptional regulation of Skp2. Therefore, the observed E2F target gene signature provides evidence that a PI3K-induced E2F node regulates p27\textsuperscript{Kip1} abundance via Skp2, which is downregulated at the mRNA and protein level upon GDC-0941 treatment (Fig. 6E and Supplementary Fig. S7D) and regulates p27\textsuperscript{Kip1} protein abundance in ECC cells (Fig. 6F). Accordingly, the Biocarta p27 pathway is significantly altered in Pik3ca\textsuperscript{H1047R}-driven ECC cells upon GDC-0941 treatment (Supplementary Fig. S7D). For Kras-driven PDAC, we could not detect any significantly altered pathway, because of the low number of significantly differentially expressed genes. These findings support the view that PI3K pathway activation by oncogenic Kras\textsuperscript{G12D} does not reach a critical threshold that is necessary to alter the p27 network and downregulate p27\textsuperscript{Kip1} protein abundance, which is necessary for ECC induction.
To gain more insights into the context-specific transcriptional control of the p27Kip1 network under basal conditions, we analyzed the top 10 differentially targeting transcription factors (TFs) in Pik3caH1047R-driven ECC and KrasG12D-induced PDAC. We observed fundamental differences in p27Kip1 network regulation, and identified context-specific TFs that control the p27Kip1 tumor suppressor node specifically in ECC (Supplementary Fig. S7E).

To analyze p27Kip1 function in the extrahepatic biliary epithelium, we investigated early events of tumorigenesis. Surprisingly, p27Kip1 inactivation triggered senescence of the normal biliary epithelium in the absence of an oncogene. In contrast, it bypassed oncogene-induced senescence in the context of Pik3caH1047R-induced early neoplastic BillIN lesions (Fig. 7D and supplementary graphical abstract). Importantly, these BillIN lesions showed concomitant increased proliferation rates as evidenced by Ki67 immunohistochemistry in situ (Fig. 7E, F). In line, CRISPR/Cas9 mediated deletion of p27Kip1 in primary low passaged ECC cells derived from the Pik3caH1047R model induced cell proliferation and cell cycle progression (Fig. 7G and Supplementary Fig. S8A, B).

These results provide evidence that canonical p27Kip1 tumor suppressor functions, which regulate G0 to M phase cell cycle transitions, contribute significantly to the observed effects, although the importance of additional and alternate effectors of p27Kip1 cannot be completely excluded (42).

To further substantiate our hypothesis that p27Kip1 is also a roadblock in human BTC, we analyzed p27Kip1 expression in 221 primary surgically resected tumor specimens. In accordance with the murine in vivo studies, we observed weak or absent p27Kip1 expression in nearly all human BTC (weak or absent p27Kip1: n=209; strong p27Kip1: n=12) specimens (Fig. 7H). In addition, tumors with weak or absent p27Kip1 expression were associated with poor survival. Kaplan-Meier curves comparing p27Kip1 expression with survival showed a trend towards separation (p = 0.08, log-rank test; Fig. 7I). This is in accordance with previous studies, reporting that p27Kip1 protein abundance is an independent predictor of survival for patients with cholangiocarcinoma (53,57-59).
Discussion

There have been no major improvements in the treatment of extrahepatic cholangiocarcinoma in the last 3 decades and no effective targeted therapies are available (1-3). Next generation sequencing and molecular tumor profiling uncovered a plethora of potentially actionable molecular alterations associated with ECC malignancy (3,13,19-23). However, despite these exciting new data describing the genomic landscape of ECC, we are far from understanding the functional consequences of these genetic alterations and the underlying tumor biology. This is due to (i) the inherent limitations of current cancer genome analysis to distinguish driver and passenger mutations and to predict the functional consequences of missense mutations; (ii) the often descriptive nature of such data; (iii) the complexity of signaling processes and tumor suppressor barriers downstream of altered genes; (iv) context-specific differences between different cancer entities; (v) tumor heterogeneity; and (vi) a lack of understanding of signals form the tumor micro- and macroenvironment. Thus, there is an urgent need for complementary functional studies using informative and predictive model systems, which fill the gap between the genetic landscape and the largely unknown biology of ECC (2,3). This offers the best means of identifying novel therapeutic approaches for extrahepatic cholangiocarcinoma that are robust and effective in the clinic (60,61).

Genetically engineered mouse models (GEMMs) have been developed for diverse cancer types in the last two decades that faithfully recapitulate the histological, molecular, genetic and clinical hallmarks of the human disease (60). They are often based on the Cre/loxP system and tissue specific expression of oncogenes and/or deletion of TSGs (62). Such conditional models have provided important information about the natural biology of many cancer types and revealed potential targets for early detection and therapeutic intervention (61,63). Accordingly, they have become one of the gold standards for pre-clinical investigation of novel lead compounds and therapeutic regimes (60,61).

For ECC research, many sophisticated tools of fundamental importance, such as conditional GEMMs, have not been developed so far. This represents a major bottleneck, which is rate-limiting for pre-clinical research and explains in part the poor molecular understanding of this devastating disease (1,12,19). We addressed this limitation and developed novel GEMMs of oncogenic Kras- and Pi3k-driven ECC.
subtypes that exhibit hallmarks of the human disease; from multistage BilIN precursor lesion progression to invasive stroma-rich ductal adenocarcinomas (see supplementary graphical abstract for an overview of the models).

The pathogenesis of human ECC is a complex process involving alterations in the activity of multiple oncogenes and TSGs and their downstream effector pathways (1,3,64). Of these, activation of RAS- and PI3K-signalling pathways represents the most frequent events (3). Our new autochthonous ECC models offer for the first time the possibility to (i) study the biology of these molecular cancer subtypes and their associated pathways, (ii) discover and validate therapeutic targets, and (iii) provide the context for pre-clinical trials to find new ways to treat ECC subtypes and identify biomarkers of response and resistance.

We employed the novel Pik3ca\textsuperscript{H1047R}-driven GEMM of ECC to perform a large genome-wide unbiased functional transposon-based mutagenesis screen to discover cooperating cancer genes in ECC. Using the piggyBac transposition system, we identified many novel cancer genes and cancer driving networks. Some of them specifically feed into the PI3k-pathway, such as inactivation of Pten or Lats1, or drive inactivation of the tumor suppressor \textit{p27\textsuperscript{Kip1}} (\textit{Cdkn1b}), which we identified as a major roadblock for ECC pathogenesis. Subsequently, we validated the essential role of PI3K-signalling output strength and \textit{p27\textsuperscript{Kip1}} down regulation for ECC formation \textit{in vivo} using \textit{Kras\textsuperscript{G12D}}, and Pik3ca\textsuperscript{H1047R}-driven GEMMs with genetic alteration in these pathways (please see the supplementary graphical abstract for an overview of the tissue specific tumor suppressor barriers of ECC formation).

\textit{p27\textsuperscript{Kip1}} is a cyclin-dependent kinase (CDK) inhibitor and one of the most frequently misregulated proteins in human cancers. It is an atypical tumor suppressor gene, as it is rarely mutated or deleted; rather, p27 protein levels are reduced or the protein is mislocalized, which promotes uncontrolled cell growth (42). Our data suggest that a certain level of PI3K output is necessary to block \textit{p27\textsuperscript{Kip1}} expression to a level that allows extrahepatic bile duct cancer formation. To test this hypothesis, we overactivated the PI3K pathway \textit{in vivo} and observed decreased \textit{p27\textsuperscript{Kip1}} levels and accelerated extrahepatic cholangiocarcinoma formation. In line, genetic manipulation of \textit{p27\textsuperscript{Kip1}} (\textit{Cdkn1b}) expression using knock-out mice validated its role as a roadblock for ECC pathogenesis in the PI3K-driven model. In contrast to Pik3ca\textsuperscript{H1047R}, activation of oncogenic \textit{Kras\textsuperscript{G12D}}-induced tumor development only in the pancreas, but
completely failed to drive ECC. However, deletion of p27^kip1 (Cdkn1b) enabled Kras-driven tumorigenesis in the extrahepatic bile duct with high penetrance. Because the TSG p27^kip1 is tightly linked to PI3K-signalling (42,54,55), our genetic in vivo data show for the first time that a PI3K-p27^kip1 node is an essential determinant of PI3K- as well as Kras-driven ECC development (see supplementary graphical abstract). This has important therapeutic implications, because several pharmacological inhibitors directed against the PI3K pathway are under clinical investigation and drugs that combat p27^kip1 dysfunction are currently under development (48,65).

Our data allow two important conclusions. First, the response and vulnerability to distinct oncogenic drivers, allowing or preventing cancer development at different anatomical sites, is strictly tissue-specific, even if the different tissue types have a common developmental origin and indistinguishable morphology, as shown for the extrahepatic bile duct and the pancreatic duct. Second, distinct tumor suppressor barriers and signaling thresholds are operative in different tissue types, even in the presence of the same initial oncogenic lesion as shown for Kras^G12D and p27^kip1 in the extrahepatic bile duct and the pancreas. Thus, our results demonstrate that tissue-specific mechanisms contribute significantly to the context-specific oncogenic potency of a cancer driver and support the view that each tissue has its own unique signaling requirement during oncogene-induced transformation. This provides in vivo evidence for the rationale to investigate Kras- and PI3K-driven oncogenic pathways in a strictly tissue- and context-specific manner to characterize the relevant nodes engaged in different tumor entities. Tissue-context is an important determinant of treatment response and resistance. Therefore, the advance in our understanding of tissue-specific effects of oncogenic Kras- and PI3K-signalling presented here, will impact clinical practice in the future since it clearly shows that results obtained in one tumor entity cannot simply be extrapolated to another.

In conclusion, our findings establish cell context-specific functions for Kras- and PI3K-signalling and engagement of p27^kip1 in transformation of the extrahepatic bile duct that are independent of the Trp53 pathway. They also suggest that the role of oncogenic drivers vary, depending on the cell and tissue type and its microenvironment. Our findings underscore that tissue context is an important determinant of tumorigenesis. A deeper understanding of the molecular mechanisms involved in ECC pathogenesis and tumor biology will provide novel therapeutic targets and biomarkers of response essentially needed for clinical decision-making and the
design of novel and improved next-generation targeted treatment regimens for ECC patients.
Methods

Mouse strains and tumor models

*Pdx1-Cre* (16), *LSL-R26rtomato/+* (17), *R26rT-mG/+* (18), *LSL-Pik3ca^{H1047R/+}* (24), *LSL-Kras^{G12D/+}* (16), *Trp53^{f/f}* (35), *p27^{-/-}* (56), *LSL-R26{PB/+}* (14), *ATP1-S2* (15), and *Pten^{f/+}* (39) alleles have been previously described. All animal studies were conducted in compliance with European guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committees (IACUC) of Technische Universität München, Regierung von Oberbayern and UK Home Office. Animals on a mixed C57Bl6/129S6 genetic background were intercrossed to obtain the desired genotype and both male and female mice with the correct genotype were aged to assess cancer formation and survival of the animals. Wildtype and animals containing only Cre recombinase served as controls as indicated in the figure legends. Sequence information of genotyping PCR primers is given in the Supplementary Methods.

Materials

Cell culture reagents were obtained from Thermo Fisher Scientific (Waltham, USA). Primers were made by Eurofins Genomics (Ebersberg, Germany) and restriction endonucleases obtained from New England Biolabs (Mannheim, Germany). The *E. coli* strain Stbl3 (Thermo Fisher Scientific) was used for transformation and plasmid amplification. The PI3K inhibitor GDC-0941 free base was purchased from LC Laboratories (Woburn, MA, USA). The SKP2 inhibitor SKP2inC1 was purchased from Selleckchem (Houston, TX, USA).

White light and fluorescence stereomicroscopy

Macroscopic pathological analysis of murine tissues including ECC and PDAC was performed and white-light and fluorescence pictures were taken by using a Zeiss Stemi 11 fluorescence stereomicroscope (Zeiss, Oberkochen, Germany).

Histopathology and immunohistochemistry

Mouse tissue specimens were fixed in 4% buffered formalin overnight, embedded in paraffin and sectioned (2 µm thick). Murine PanIN lesions and PDAC were graded according to the established nomenclature (66). Murine biliary intraepithelial neoplasia (BillN) were graded in analogy to the human classification (27,67). The normal common bile duct in mice is morphologically similar to its human counterpart. It is lined
by a single layer of uniform cuboidal cells and accompanied by small peribiliary glands. Proliferative lesions with a flat or micropapillary structure composed of tall columnar cells with some loss of cellular polarity and/or nuclear pseudostratification with mild nuclear abnormalities (i.e. slight hyperchromasia or irregular nuclear membrane) were categorized as low grade BilIN. High grade BilIN were defined as lesions with micropapillary architecture and diffuse loss of cellular polarity, ‘budding off’ of single epithelial cells into the lumen and severe cellular and nuclear pleomorphism. By definition, invasion through the basement membrane had to be absent in these strictly intraepithelial lesions. The examiner was blinded to the genotype of the animals. For immunodetection, formalin-fixed paraffin-embedded tissue sections were dewaxed, rehydrated and placed in a microwave (10 min, 600 watt) in unmasking solution H-3300 (Vector Laboratories, Burlingame, CA) to recover antigens. Sections were incubated with primary pERK (p44/42) (#4376; 1:1000, RRID:AB_331772); Cleaved Caspase-3 (#9664; 1:150, RRID:AB_2070042); PIK3CA (p110α) (#4249; 1:400, RRID:AB_2165248); pAKT-T308 (#2965; 1:50, RRID:AB_2255933); pAKT-S473 (#4060; 1:50, RRID:AB_2315049); pGSK3β−S9 (#9323; 1:100, RRID:AB_2115201; all from Cell Signaling Technology, Danvers, MA), p21 (sc-397-G; 1:50; RRID:AB_632127; Santa Cruz Biotechnology, Santa Cruz, CA), p53 (CM5; 1:300; RRID:AB_2744683; Novocastra/Leica Mikrosysteme, Wetzlar, Germany), p27Kip1 (ab62364, RRID:AB_944575; 1:500, Abcam plc, Cambridge, UK), and Ki67 (SP6, 1:50, RRID:AB_2722785; DCS Diagnostics, Hamburg, Germany) antibodies followed by a secondary antibody conjugated to biotin (Vector Laboratories). Antibody detection of pERK, Cleaved Caspase-3, PIK3CA (p110α) was performed with the Bond Polymer Refine Detection Kit (Leica). Images were acquired using Leica AT2 Scanner (Leica). Quantification of p27Kip1, Cleaved Caspase-3 and Ki67 positive cells was performed by exclusively counting epithelial cells in at least ten high power fields (HPF) in at least 3 animals and the examiner was blinded to the genotype of the animals.

**Senescence-associated β-galactosidase (SA-β-gal) staining**

SA-β-galactosidase staining of cryosections was performed with the Senescence β-Galactosidase Staining Kit in accordance with the Manufacturer’s protocol (Cell Signaling Technology). Counterstaining was carried out with nuclear fast red. Images were acquired using Aperio Versa Scanner (Leica).

**Immunofluorescence and confocal laser-scanning microscopy**

22
Tissues were fixed in 4% buffered formalin for 2 h, dehydrated at 4 °C (15% sucrose in PBS for 4 h; 30% sucrose in PBS overnight) and embedded in Tissue-Tek® (Sakura, Torrance, CA) before being frozen in liquid nitrogen. 20 µm thick frozen sections were post-fixed for 1 min in 4% buffered formalin, washed twice in PBS and incubated for 1 h in PBS with 3% (w/v) bovine serum albumin (BSA), 1% (w/v) Saponin and 1% (v/v) Triton-X 100. Subsequently, slides were incubated with CK19 primary antibody (1:100, ab62364, Abcam) and a DyLight 680 conjugated secondary antibody (Cell Signaling Technology, Danvers, USA). Nuclei were counterstained with TOPRO®-3-iodide (1:1000, Thermo Fisher Scientific). Sections were examined on a Leica TCS SP5 DMI 6000 CS cofocal laser-scanning microscope using a 40/1.25 oil-immersion objective (Leica Microsystems, Wetzlar, Germany).

**Human BTC tissue samples**

This study conformed to the Declaration of Helsinki and was approved by the ethics committee of the Universität Heidelberg. Written informed consent was obtained from all patients. The use of the tissue for this study was approved by the institutional ethics committee (206/05). Our cohort comprised 221 patients with cholangiocarcinoma (CC). All tumors were resected between 1995 and 2010 at the University Hospital in Heidelberg, Germany. Neoadjuvant radio- and/or chemotherapy was not applied in any of the patients. 123 (55.7%) patients were male, 98 (44.3%) were female. Mean age at diagnosis was 64.7 years (range: 33.5 to 91.6 years). 27 (12.2%) tumors were classified as pT1, 116 (52.5%) were pT2, 61 (27.6%) were pT3 and 17 (7.7%) were pT4. 151 (68.3%) of the patients received concomitant lymph node resection. Of these 83 (55%) were pN1 and 68 (45%) were pN0. 19 patients (8.6%) had distant metastasis at the time of resection. 57 (25.8%) of the tumors were intrahepatic cholangiocarcinomas, 94 (42.5%) of the tumors were extrahepatic cholangiocarcinomas and 70 (31.7%) of the tumors were gallbladder carcinomas. Of 191 patients (86.4%) follow up data were available. Mean follow-up time of patients alive at the endpoint of analysis was 45.7 months. 125 (65.4%) patients died during follow up.

**Evaluation of the human BTC cohort**

From all 221 cholangiocarcinomas, 3μm sections were cut and stained with H&E. Representative areas from the tumor center and invasive margins were marked by two pathologists with a special expertise in CC pathology (BG and WW). For each case,
tumor tissue cores (1.5 mm diameter) from the selected representative tumor areas were punched out of the sample tissue blocks and embedded into a new paraffin array block using a tissue microarrayer (Beecher Instruments, Woodland, CA, USA). For the detection of p27*Kip1, a monoclonal mouse IgG antibody directed against p27*Kip1 (BD Biosciences, Heidelberg, Germany; Clone: 57/Kip1/p27 (RUO); #610242; 1:100 dilution, RRID:AB_397637) was used. Bound antibody was detected with the Dako K5003 AEC kit (Dako, Hamburg, Germany). To exclude cases with only faint and focal putatively biologically irrelevant p27*Kip1 expression from the p27*Kip1 “positive” group, cases were only scored as positive when a clearly distinguishable nuclear signal of at least moderate intensity was seen in more than 50% of tumor cells.

Mapping of transposon insertion sequences to the mouse genome and identification of common insertion sites

Genomic DNA was isolated from fresh frozen ECC samples with the QIAamp DNA Mini Kit according to the manufacturer’s protocol. Amplification of the transposon insertion sites and next generation sequencing on an Illumina MySeq desktop sequencer was performed as described (14). Transposon insertion sites with a coverage of 2 or more reads were subjected to TAPDANCE analysis to identify nonredundant common insertion sites (CIS) (36). Network analysis was conducted with STRING (38).

Generation and cultivation of primary low-passaged dispersed murine ECC and PDAC cell cultures

Primary dispersed murine ECC and PDAC cell cultures were established from Pdx1-Cre;LSL-Pik3caH1047R/+ and Pdx1-Cre;LSL-KrasG12D/+ mice, and cultivated as previously described (68). Cell viability was quantified using MTT-assay using the substrate 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (Sigma-Aldrich Chemie, Taufkirchen, Germany). All cell lines were authenticated by genotyping and tested negative for mycoplasma contamination by an inhouse PCR-based mycoplasma detection assay every two months. The low-passaged cell cultures were cultivated for a maximum of 20 passages and used typically for the experiments between passage 5 and 10.

Drug treatment
Cells were seeded in a 10 cm dish and treated 24 hours later with GDC-0941 or SKP2inC1 at the indicated concentrations, or vehicle for 24 or 48 hours as indicated. The medium containing either the drug or the vehicle was changed after 24 hours.

**Gene expression profiling and analysis**

RNA was isolated with the RNeasy kit (Qiagen) from 80% confluent primary cells and immediately transferred into RLT buffer (Qiagen) containing β-mercaptoethanol.

RNA-seq library preparation was performed as previously described (69). Analyses were carried out using R version 3.6.2 and Bioconductor version 3.1. Differential gene expression analysis was performed using DESeq2 version 1.26.0. A gene was considered to be differentially expressed with a Benjamini-Hochberg adjusted p-value of 0.05 and an absolute fold change >0.5. The over-representation analysis was performed with MSigDB v7.1 gene sets provided by Broad Institute, Massachusetts Institute of Technology and Harvard University.

RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-10515.

To investigate the tissue specific regulatory networks of the p27^Kip1 pathway, we used PANDA. PANDA integrates multiple types of data including protein-protein interactions (PPI) and gene expression to infer interaction between transcription factors (TFs) and their target genes (70). We used the netZooR implementation of PANDA (version 0.9) to infer 2 separate regulatory networks for Pik3ca^H1047R- driven ECC and Kras^G12D- driven PDAC. For each network, we used the same TF/target prior and PPI networks and normalized tissue-specific gene expression data. The TF/gene prior was downloaded from https://sites.google.com/a/channing.harvard.edu/kimberlyglass/tools/resources. The PPI network was downloaded from STRINGdb, integrated in the netZooR library. The resulting networks allowed us to analyze the behavior of 441 TFs, >18,000 genes and more than 8 million weighted edges between them. The visualization of the p27^Kip1- related subnetworks was done in Cytoscape (v3.8.2, https://cytoscape.org).

**CRISPR-Cas9-mediated p27^Kip1 deletion in primary murine ECC cell lines**

Two different sgRNAs targeting exon 1 of the Cdkn1b (p27^Kip1) gene were designed using the online tool CRISPR Design (http://crispr.mit.edu/job/4733254127165968,1.8.2014). The Cas9 expression vector
pSpCas9(BB)-2A-Puro (pX459) (Addgene plasmid #48139; www.addgene.org) was used to insert either the annealed sgRNA1 or sgRNA2 both targeting Cdkn1b (p27Kip1). Sequence information of the sgRNAs is provided in the Supplementary Methods. Primary low-passaged murine ECC cells were co-transfected with the two modified versions of pX459 containing either sgRNA1 or sgRNA2 using Lipofectamine 2000 reagent according to the manufacturer's protocol (Invitrogen). For MOCK cells, cell lines were transfected with a modified version of the Cas9 nickase expression vector pSpCas9n(BB)-2A-Puro (pX462) (Addgene plasmid #48141; www.addgene.org) containing only sgRNA1. Transfected cells were selected 24h later by addition of puromycin to the culture medium (2.5µg/ml). Cell viability of passaged cell lines was determined daily for 96 hours by MTT assay or cell proliferation was assessed by cell counting.

**Quantitative reverse-transcriptase PCR**

Total RNA was isolated from primary ECC cell lines using the RNeasy kit (Qiagen, Hilden, Germany) following the manufacturer's instructions and reverse transcribed (Thermo Fisher Scientific). Relative mRNA quantification using cyclophilin as reference gene was performed by real-time PCR analysis (TaqMan, PE Applied Biosystems, Norwalk, CT). Sequence information of the qRT-PCR primers is provided in the Supplementary Methods.

**Cell cycle analysis by flow cytometry**

To synchronize the cell cultures, cells were seeded in 10 cm dishes in growth medium with 10% FCS overnight. The cultures were then washed by PBS and changed to serum free medium. After 24 h serum starvation, the cells were passaged and released into cell cycle by addition of serum for 6 h. Cells were trypsinized and washed two times with PBS followed by fixation in 1 ml cold 70% EtOH. The EtOH was removed after 24 h and cells washed with PBS. Cells were stained with DAPI (Sigma, 1:6000) and acquired using Cytoflex LX (Beckman Coulter, Krefeld, Germany). Flow cytometry data was analyzed using FlowJo software (Version 10.6.2).

**Preparation of total cell lysates and immunoblotting**

Whole-cell lysates were prepared and isolated proteins separated in SDS-polyacrylamide gels, transferred to polyvinylidene difluoride membranes and incubated at 4°C overnight with the following primary antibodies: pAKT-T308 (#2965,
RRID:AB_2255933, pAKT-S473 (#4060, RRID:AB_2315049), pan-AKT (#4691, RRID:AB_915783), p-S6-S235/236 (#4858, RRID:AB_916156; all from Cell Signaling Technology) and p27Kip1 (sc528, RRID:AB_632129), Skp2 (sc7164, RRID:AB_2187650) and Hsp90 alpha/beta (sc13119, RRID:AB_675659; all from Santa Cruz Biotechnology). Primary antibodies were followed by Alexa680-coupled secondary antibodies (Thermo Fisher Scientific) and detected by the Odyssey Infrared Imaging System (Licor, Bad Homburg, Germany).

Data Analysis

Unless otherwise indicated, all data were determined from at least three independent experiments and expressed as mean values ±SEM. GraphPad Prism (versions 5 and 8) (La Jolla, CA, USA) was used for graphical presentation of the data and calculation of statistical tests except for the Wilcoxon Rank Sum test. The Wilcoxon Rank Sum test was computed in R Language. Statistical tests and p-values are provided in the figure legends. Values of p = 0.05 or less were considered to be statistically significant.

Supplemental Information

Supplemental Information includes one supplementary graphical abstract, eight Supplemental Figures, Supplementary Methods and one Supplemental Table and can be found with this article online.

Author contributions


References


Figure Legends

Figure 1: Constitutive activation of the PI3K-signaling pathway induces premalignant biliary intraepithelial neoplasia (BilIN). (A) Left panel: Genetic strategy and recombination scheme to analyze the patterns of Pdx1-Cre transgene expression using a conditional tdTomato reporter allele (LSL-R26tdTomato/+) (C). Right panel: Macroscopic fluorescence and white light images of Pdx1-Cre;LSL-R26tdTomato/+ reporter mouse. Visualization of tdTomato reveals reporter gene expression (red) in the pancreas, duodenum, gallbladder and common bile duct (CBD). Scale bars, 1 cm. (B) Left panel: Genetic strategy and recombination scheme to analyze the patterns of Pdx1-Cre transgene expression using a switchable floxed double color fluorescent tdTomato-EGFP Cre reporter line (R26mT-mG/). Right panel, left image: Representative confocal microscopic image of tdTomato (red color, non Cre-recombined cells) and Cre-induced EGFP (green color) expression in the common bile duct. Note: Cre-mediated EGFP expression in the biliary epithelium and peribiliary glands, but not stromal cells. Nuclei were counterstained with TOPRO-3 (blue). Right image: Representative immunofluorescence staining of CK19 (red color) of Pdx1-Cre;R26mT-mG/+ animal. Note: Blue color shows expression of tdTomato in unrecombined cells. Green color labels Cre-recombined cells that express EGFP. Co-localization of CK19 immunofluorescence staining (red) and EGFP expression (green) results in yellow color. Scale bars, 50 µm. (C-E) Genetic strategy used to express oncogenic Pik3caH1047R (C), KrasG12D (D), or only Cre as control (E) in the common bile duct. H&E staining and immunohistochemical analysis of PI3K/AKT pathway activation in the biliary epithelium of the common bile duct and different grades of dysplasia in biliary intraepithelial neoplasia (BilIN) (lower panels). Scale bars, 50 µm for micrographs and 20 µm for insets.

Figure 2: Expression of oncogenic Pik3caH1047R but not KrasG12D induces extrahepatic cholangiocarcinoma (ECC). (A) Representative in situ images of 12-month-old wildtype (control), Pdx1-Cre;LSL-Pik3caH1047R/+ and Pdx1-Cre;LSL-KrasG12D/+ mice. The common bile duct is outlined by a white dashed line. Scale bars, 1 cm. (B) Representative H&E stainings and immunohistochemical analyses of PI3K/AKT pathway activation in the common bile duct of aged Pdx1-Cre;LSL-Pik3caH1047R/+ mice with invasive ECC. Scale bars, 50 µm for micrographs and 20 µm
for insets. (C) Kaplan-Meier survival curves of the indicated genotypes (n.s., not significant; ***, p<0.001, log rank test). (D) Tumor type distribution in % according to histological analysis of the extrahepatic bile duct and the pancreas from Pdx1-Cre;LSL-KrasG12D/+ and Pdx1-Cre;LSL-Pik3caH1047R/+ mice. ECC, extrahepatic cholangiocarcinoma, PDAC, pancreatic ductal adenocarcinoma.

Figure 3: Oncogenic PI3K signaling induces senescence in the extrahepatic bile duct that is independent of the Trp53 pathway. (A) Left panel: Representative senescence associated β-galactosidase (SA-β-Gal) staining, and Trp53 and p21 immunohistochemistry of BilIN (upper panel) and PanIN (lower panel) lesions of Pdx1-Cre;Pik3caH1047R/+ mouse. Right panel: Representative SA-β-Gal staining of wildtype extrahepatic bile duct and pancreas. Scale bars, 20 µm. (B) Representative immunohistochemical cleaved caspase 3 staining of BilIN and ADM/PanIN of Pdx1-Cre;LSL-Pik3caH1047R/+ mouse and ADM/PanIN of Pdx1-Cre;LSL-KrasG12D/+ mouse. Scale bars, 50 µm. (C) Quantification of cleaved caspase 3 positive epithelial cells in BilIN and ADM/PanIN lesions of the indicated genotypes. Each dot represents one animal (mean ± s.d.; p values are indicated, two-tailed Student's t-test). (D) Kaplan-Meier survival curves of the indicated genotypes (** p<0.01; ***, p<0.001, log rank test). (E) Upper panel: Tumor type distribution according to histological analysis of the extrahepatic bile duct and pancreas of Pdx1-Cre;LSL-Pik3caH1047R/+;Pdx1-Cre;LSL-Pik3caH1047R/+;p53+/+ and Pdx1-Cre;LSL-Pik3caH1047R/+;p53−/− mice. Note: Reduced ECC fraction in mice with the Pdx1-Cre;Pik3caH1047R/+;p53−/− genotype (p=0.02, Fisher's exact test). Lower panel: Tumor type distribution according to histological analysis of the extrahepatic bile duct and pancreas of Pdx1-Cre;LSL-KrasG12D/+ and Pdx1-Cre;LSL-KrasG12D/+;p53−/− mice. (F) Representative H&E staining of ECC and PDAC of Pdx1-Cre;LSL-Pik3caH1047R/+;p53+/+ and Pdx1-Cre;LSL-Pik3caH1047R/+;p53−/− mice. (G) Representative H&E staining of the common bile duct and PDAC of Pdx1-Cre;LSL-KrasG12D/+;p53−/− mouse. Scale bars, 50 µm for micrographs and 20 µm for insets. Note: The Pdx1-Cre;Pik3caH1047R/+ and Pdx1-Cre;LSL-KrasG12D/+ cohorts shown in panel D and E are the same as shown in Fig. 2C and D.

Figure 4: Identification of cancer genes in the extrahepatic biliary tract by a piggyBac transposon mutagenesis screen. (A) Genetic strategy used to activate
ATP-S2 transposons by the piggyBac (PB) transposase in a Pdx1-Cre;LSL-Pik3ca^{H1047R/+} mutant background. pA, poly adenylation site; SA, splice acceptor; SD, splice donor; iPBase, insect version of the piggyBac transposase; CAG, CAG promoter. The ATP1-S2 mouse line carries 20 copies of the transposon construct on chromosome 10, which can be mobilized by the piggyBac transposase. Unidirectional integration of the transposon can lead to gene activation through its CAG promoter. Gene inactivation is independent of transposon orientation.

(B) Kaplan-Meier survival curves of the indicated genotypes (***, p<0.001, log rank test). Note: The Pdx1-Cre;Pik3ca^{H1047R/+} cohort is the same as shown in Fig. 2C.

(C) Tumor type distribution according to histological analysis of the extrahepatic bile duct and pancreas from Pdx1-Cre;LSL-Pik3ca^{H1047R/+} and Pdx1-Cre;LSL-Pik3ca^{H1047R/+};LSL-R26^{PB};ATP1-S2 mice. (D) Representative H&E stainings of four individual piggyBac-induced ECC of Pdx1-Cre;LSL-Pik3ca^{H1047R/+};LSL-R26^{PB};ATP1-S2 mice. Scale bars, 50 µm for micrographs and 20 µm for insets. (E) Genome-wide representation of transposon insertion densities in ECCs (pooled data from 17 tumors). Selected common insertion site (CIS) genes are depicted. Chromosomes are labeled by different colors and chromosome number is indicated on the x-axis. The transposon donor locus is on chromosome 10. Each column represents one tumor where insertions in the respective genes are indicated in blue. The fraction of tumors carrying an insertion in the respective genes is given as percentage. (G) Network of protein interactions between CIS genes generated by STRING analysis (38). Each network node represents one protein. Interactions are marked by lines in different colors (green, neighborhood evidence; purple, experimental evidence; light blue, database evidence; black, co-expression evidence). Cdkn1b, p27^{kip1}.

Figure 5: Functional validation of transposon integrations: PI3K signaling output is a critical determinant of ECC development. (A) piggyBac insertion patterns in Pten. Pten possesses one protein-coding isoform consisting of 9 exons. Each arrow represents one insertion and indicates the orientation of the CAG promoter that was introduced into the transposon. (B) Upper panel: Genetic strategy used to inactivate Pten in the Pdx1 lineage using a Pdx1-Cre line. Lower panel: Representative macroscopic picture (left, bile duct depicted by a white dashed line) and H&E stained tissue section (right) of an ECC from a Pdx1-Cre;Pten^{f/f} mouse. Scale bars, 50 µm for...
micrographs and 50 μm for insets. (C) Kaplan-Meier survival curves of the indicated genotypes (*** p<0.001, log rank test). Note: The Pdx1-Cre;Pik3ca\(^{H1047R/+}\) and the control cohort is the same as shown in Fig. 2C. (D) Tumor type distribution according to histological analysis of the bile duct and pancreas from Pdx1-Cre;Pten\(^{ff}\), Pdx1-Cre;LSL-Pik3ca\(^{H1047R/+}\) and Pdx1-Cre;LSL-Pik3ca\(^{H1047R/H1047R}\) mice. Note: The Pdx1-Cre;Pik3ca\(^{H1047R/+}\) cohort is the same as shown in Fig. 2D. (E) Left panel: Representative macroscopic picture of an ECC from a Pdx1-Cre;LSL-Pik3ca\(^{H1047R/H1047R}\) mouse. Scale bar, 1 cm. Middle and right panel: Representative H&E (middle) and immunohistochemical CK19 (right) stained tissue section of an ECC from a Pdx1-Cre;Pik3ca\(^{H1047R/+}\) mouse. Scale bars, 50 μm for micrographs and 20 μm for insets. (F) Representative H&E stainings and immunohistochemical analyses of PI3K/AKT pathway activation and Pik3ca (p110α) expression in the common bile duct of Pdx1-Cre;LSL-Pik3ca\(^{H1047R/+}\), Pdx1-Cre;LSL-Pik3ca\(^{H1047R/H1047R}\) and Pdx1-Cre;Pten\(^{ff}\) mice. Scale bars, 50 μm.

**Figure 6: p27\(^{Kip1}\) (Cdkn1b) expression is downregulated by mutant PIK3CA\(^{H1047R}\).**

(A) piggyBac insertion patterns for selected CIS genes implicated in p27\(^{Kip1}\) (Cdkn1b) regulation. Ppmb1b and Fbxw7 possess four protein-coding transcripts. Frk has two protein-coding isoforms consisting of 8 and 9 exons. Each arrow represents one insertion and indicates the orientation of the CAG promoter that was introduced into the transposon. (B) Representative immunohistochemical analysis of p27\(^{Kip1}\) expression in the common bile duct of 6 months old wildtype, Pdx1-Cre;LSL-Pik3ca\(^{H1047R/+}\) and Pdx1-Cre;LSL-Kras\(^{G12D/+}\) mice. Scale bars, 80 μm (upper panel), 20 μm (middle panel and lower panel). Note: IHC staining was performed using 3-amino-9-ethylcarbazole (AEC) as chromogen resulting in a pink color of positively stained cells. (C) Quantification of p27\(^{Kip1}\) positive bile duct epithelial cells in 6-months-old wildtype, Pdx1-Cre;LSL-Pik3ca\(^{H1047R/+}\), Pdx1-Cre;LSL-Pik3ca\(^{H1047R/H1047R}\) and Pdx1-Cre;LSL-Kras\(^{G12D/+}\) mice (n=3-4 animals per genotype). Each dot represents one animal; the horizontal line represents the mean. (p=0.05, Pdx1-Cre;LSL-Pik3ca\(^{H1047R/H1047R}\) vs. Pdx1-Cre;LSL-Kras\(^{G12D/+}\); Wilcoxon Rank Sum test). (D) qRT-PCR analysis of p27\(^{Kip1}\) mRNA expression in three primary murine ECC cell lines from Pdx1-Cre;LSL-Pik3ca\(^{H1047R/+}\) mice treated with either vehicle (DMSO) or 1µM GDC-0941 for 24 or 48 hours as indicated. Data are shown as fold-change to DMSO treatment (n=3; mean + s.d.; p values are indicated, Student’s t-test). (E) Immunoblot
analysis of PI3K/AKT pathway activation and p27<sup>Kip1</sup> expression in primary murine ECC cell line #1 treated with either vehicle (DMSO) or 1µM GDC-0941 for 48 h. Hsp90α/β was used as loading control. (F) Immunoblot analysis of p27<sup>Kip1</sup> expression in primary murine ECC cell line #1 treated with either vehicle (DMSO) or the indicated concentrations of the SKP2 inhibitor SKP2in C1 for 48 h. Hsp90α/β was used as loading control.

Figure 7: p27<sup>Kip1</sup> is a context-specific roadblock for Kras-induced ECC formation. (A) Kaplan-Meier survival curves of the indicated genotypes (*** p<0.001, ** p<0.01, log rank test). (B) Tumor type distribution according to histological analysis of the extrahepatic bile duct and pancreas from Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+</sup> and Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+;p27<sup>+</sup>-</sup> mice (left panel) and Pdx1-Cre;LSL-Kras<sup>G12D/+</sup>, Pdx1-Cre;LSL-Kras<sup>G12D/+;p27<sup>+</sup>-</sup> and Pdx1-Cre;LSL-Kras<sup>G12D/+;p27<sup>+</sup>-</sup> animals (right panel). Note: Significant increase of ECC development in mice with the Pdx1-Cre;LSL-Kras<sup>G12D/+;p27<sup>+</sup>-</sup> genotype (p<0.0001, Fisher's exact test). (C) Representative H&E staining of the common bile duct of aged Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+;p27<sup>+</sup>-</sup>, Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+;p27<sup>+</sup>-</sup>, Pdx1-Cre;LSL-Kras<sup>G12D/+;p27<sup>+</sup>-</sup> and Pdx1-Cre;LSL-Kras<sup>G12D/+;p27<sup>+</sup>-</sup> mice. (D) Representative senescence associated β-galactosidase (SA-β-Gal) staining of the common bile duct of Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+;p27<sup>+</sup>-</sup>, Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+;p27<sup>+</sup>-</sup>, Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+;p27<sup>+</sup>-</sup> and p27<sup>-/-</sup> mice. C and D: Scale bars, 50 µm for micrographs and 20 µm for insets. (E) Representative images of Ki67 stained common bile duct tissue sections of 3-month-old wildtype (control), Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+</sup>, Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+;p27<sup>+</sup>-</sup>, Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+;p27<sup>+</sup>-</sup> and Pdx1-Cre;LSL-Kras<sup>G12D/+</sup> and Pdx1-Cre;LSL-Kras<sup>G12D/+;p27<sup>+</sup>-</sup> mice. Scale bars, 20 µm. (F) Quantification of Ki67 positive biliary epithelial cells of indicated genotypes. Each dot represents one animal, the horizontal line the mean. (G) Upper panel: Viability assay of primary murine ECC cell line #1 from Pdx1-Cre;LSL-Pik3ca<sup>H1047R/+</sup> mouse after CRISPR-Cas9 mediated deletion of p27<sup>Kip1</sup> (Cdkn1b). Cells were transfected with either Cas9-sgRNA-p27<sup>Kip1</sup> targeting Cdkn1b (CRISPR-Cas-p27) or a MOCK Cas9-sgRNA-MOCK vector, selected using puromycin, and cell viability was measured in triplicate using MTT assay (n=4 independent experiments, mean ± s.d., p<0.0001, 2-way ANOVA). Lower panel: FACS based cell cycle analysis of the cells shown in the upper panel. The p values were determined with multiple t tests and Benjamini
correction and are shown in the figure; n.s., not significant. (H) Quantification of p27\textsuperscript{Kip1} expression by immunohistochemistry of 221 surgically resected human biliary tract cancer (BTC) specimens. (I) Kaplan-Meier survival curves of BTC patients with low or high p27\textsuperscript{Kip1} protein abundance (p=0.08; log rank test). Note: The \textit{Pdx1-Cre};\textit{Pik3ca}H1047R/+ and \textit{Pdx1-Cre};\textit{LSL-KrasG12D/+} cohorts shown in panel A and B are the same as shown in Fig. 2C and D.
Figure 1

A

```
Pdx1 → Cre → tdTomato [loxP] → tdTomato
```

B

```
Pdx1 → Cre → tdTomato [loxP] → EGFP
```

C

```
Pdx1 → Cre → R26 "Stop" → Pref1 [loxP] → pAKT-T308 [loxP], pAKT-S473 [loxP], pGSK3β-S9 [loxP]
```

D

```
```

E

```
Pdx1 → Cre → wild type
```

**Pdx1-Cre;LSL-R26/tdTomato/Cbd:**

- Gallbladder
- Liver
- Intestine
- Pancreas

**Pdx1-Cre;LSL-R26/tdTomato/Cdk:**

- Gallbladder
- Liver
- Intestine
- Pancreas
Figure 2

A  

<table>
<thead>
<tr>
<th></th>
<th>wild type</th>
<th>Pik3ca&lt;sup&gt;H1047R&lt;/sup&gt;</th>
<th>Kras&lt;sup&gt;G12D&lt;/sup&gt;</th>
</tr>
</thead>
</table>

B  

<table>
<thead>
<tr>
<th></th>
<th>HE</th>
<th>pAKT-T308</th>
<th>pAKT-S473</th>
<th>pGSK3β-S9</th>
</tr>
</thead>
</table>

C  

![Graph showing survival over age with different line types and annotations for control, Pdx1-Cre;Kras<sup>G12D</sup>, and Pdx1-Cre;Pik3ca<sup>H1047R</sup> groups, with median survival times indicated.]

D  

![Bar chart showing tumor type distribution with ECC only, ECC and PDAC, and PDAC only categories.]

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Figure 3

A. SA-β-Gal, p53, p21, Bax, and PanIN staining in wild type and pancreas tissues.

B. Cleaved Caspase-3 staining in different genotypes.

C. Statistical analysis of Cleaved Caspase-3 positivity.

D. Survival analysis of different genotypes.

E. Tumor type distribution in different genotypes.

F. Histological images of ECC and PDAC in different genotypes.

G. Histological images of bile duct and PDAC in different genotypes.
Figure 6

A. Diagram showing expression levels of genes such as Ppm1b, Fbxw7, and Frk.

B. Images of wild type and mutant Kras (G12D) tissue sections, with panels showing expression of p27 and other proteins.

C. Graph illustrating the percentage of p27 positive cells across different conditions.

D. Bar graphs showing the mRNA expression of p27 in ECC cell lines treated with DMISO and GDC.

E. Western blot analysis showing the expression of p-AKT-Thr308, p-AKT, HSP90, and other proteins.

F. Western blot showing the effect of SKP2n C1 (μM) on P27, SKP2 (40-65 kDa), and HSP90 (90 kDa) expression.
Figure 7

A) Survival curves for different groups of mice. 
- Green line: Pdx1-Cre;Pik3ca^{1047R+} (n=10), median survival: 313 days.
- Purple line: Pdx1-Cre;Pik3ca^{1047R+};p27^{−/−} (n=18), median survival: 172.5 days.
- Orange line: Pdx1-Cre;Pik3ca^{1047R+};Kras^{G12D+} (n=38), median survival: 383 days.
- Red line: Pdx1-Cre;Pik3ca^{1047R+};p27^{−/−};Kras^{G12D+} (n=8), median survival: 227 days.
- Blue line: Pdx1-Cre;Pik3ca^{1047R+};p27^{−/−};Kras^{G12D+} (n=5), median survival: 112 days.

B) Tumor type distribution for different groups of mice. 
- Pdx1-Cre;Pik3ca^{1047R+}: p27^{−/−} (n=10), p27^{−/−} (n=14).
- Pdx1-Cre;Kras^{G12D+}: p27^{−/−} (n=22), p27^{−/−} (n=6).
- Pdx1-Cre;Pik3ca^{1047R+};p27^{−/−}: p27^{−/−} (n=4).

C) Hematoxylin and Eosin (HE) staining of tissues from different groups of mice.

D) SA-β-Gal staining of tissues from different groups of mice.

E) Ki67 staining of tissues from different groups of mice.

F) KAP1 expression levels in different groups of mice.

G) ECC cell line #1 viability over time for CRISPR-Cas-MOCK and CRISPR-Cas-p27.

H) Human BTC frequency for p27 low and p27 high groups.

I) Human BTC survival over time for p27 low (n=209) and p27 high (n=12) groups.

Downloaded from cancerdiscovery.aacrjournals.org on July 28, 2021. © 2021 American Association for Cancer Research.
Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer

Chiara Falcomata, Stefanie Barthel, Angelika Ulrich, et al.

Cancer Discov Published OnlineFirst July 19, 2021.

Updated version Access the most recent version of this article at: doi:10.1158/2159-8290.CD-21-0209

Supplementary Material Access the most recent supplemental material at: http://cancerdiscovery.aacrjournals.org/content/suppl/2021/07/15/2159-8290.CD-21-0209.DC1

Author Manuscript Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/early/2021/07/14/2159-8290.CD-21-0209.

Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.